30Nov/100
FDA staff note risks of AstraZeneca cancer drug
An experimental AstraZeneca cancer medicine carries "substantial toxicity" for patients with inoperable thyroid cancer, U.S. drug reviewers said in documents released on Tuesday.
An experimental AstraZeneca cancer medicine carries "substantial toxicity" for patients with inoperable thyroid cancer, U.S. drug reviewers said in documents released on Tuesday.